Hepatitis
Conditions
Brief summary
The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of the same outcome after introduction of Havrix™ in Panama.
Detailed description
In this study, systematic review of the databases of epidemiologic surveillance system (Ministry of Health), for hepatitis related outcomes will be performed. The analysis will be performed by age group, years and country region.
Interventions
Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
Sponsors
GlaxoSmithKline
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Hepatitis related outcomes occurred during the period analyzed and registered in the Epidemiologic Surveillance System of the Ministry of Health, will be collected for the study
Exclusion criteria
* Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of reported hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) | In post vaccine introduction period (2008-2010) compared to pre-vaccination period (2000-2007) |
Secondary
| Measure | Time frame |
|---|---|
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by year | From year 2000 until year 2010 |
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by age groups | From year 2000 until year 2010 |
| Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by region | From year 2000 until year 2010 |
Countries
Panama
Outcome results
None listed